Filament Health Completes First Export of Botanical Psilocybin to Israel

Filament Health Corp. has completed an exported of its botanical-psilocybin drug candidate to Israel, the company said.

The shipment of PEX010 is believed to be the first botanical psilocybin to be exported to Israel, according to Filament Health.

Hadassah University Hospital will study PEX010 in a clinical trial examining the effects of psilocybin for treatment-resistant obsessive-compulsive disorder (TR-OCD) and treatment-resistant post-traumatic stress disorder (TR-PTSD).

“There is a growing need for research into mental health conditions like TR-PTSD and TR-OCD, and psychedelic-assisted psychotherapy shows significant promise for treating both of these conditions,” said Dr. Ronen Segman, associate professor of psychiatry at Hadassah University Hospital.

Despite decades of research, therapeutic options for chronic PTSD are mostly limited to rehabilitation and symptom relief, “resulting in substantial unmet need for a solution,” Filament Health asserted.

Preliminary research into psychedelic-assisted psychotherapy for OCD has demonstrated a decrease in symptoms, pointing to the necessity for controlled proof-of-concept trials to further substantiate its safety and efficacy for TR-OCD.

“The successful export of PEX010 to Israel is a major achievement for our team,” said Lisa Ranken, COO at Filament Health. “Filament is one of the largest – if not the largest – supplier of psilocybin globally, and we are pleased to add Israel to the growing list of jurisdictions where our drug candidate will be under investigation.”

The clinical trial at Hadassah University Hospital is the 28th study globally that is investigating Filament’s psilocybin drug candidate for 12 mental-health conditions, including opioid-use disorder, alcohol-use disorder, depression and coma, according to the company.

Burnaby, British Columbia-based Filament also has supplied PEX010 to clinical trials in Europe, Canada and the United States.